34 results about "Topical drug" patented technology

Provided herein are methods for treating skin-related diseases or disorders (e.g., melasma). Also provided are pharmaceutical compositions of midostaurin or a pharmaceutically acceptable salt thereof formulated for topical administration. Also described are methods for preparing such topical pharmaceutical compositions and methods for using the topical pharmaceutical compositions to treat a subject.

The invention belongs to the field of biological medicine, and particularly relates to lipid nanoparticles for local drug delivery, a preparation method of the lipid nanoparticles and application of the lipid nanoparticles to preparation of anti-scar drugs. The lipid nanoparticle comprises a lipid carrier and nucleic acid wrapped by the lipid carrier, and the lipid carrier comprises the following components: an ionizable lipid, a permanent cationic lipid, a pegylated lipid, an auxiliary phospholipid and a sterol compound; the molar ratio of the ionizable lipid to the permanent cationic lipid to the pegylated lipid to the auxiliary phospholipid to the sterol compound is (25-45): (5-25): (1-2): (5-15): (35-40). In order to solve the problem of single administration of lipid nanoparticles in the prior art, the lipid nanoparticles are designed to be externally applied and applied for local administration through proportion regulation and control, so that the targeting property is improved, and the administration concentration is increased. Whole-body blood circulation is avoided, and toxic and side effects and off-target performance are reduced. Therefore, the dual purposes of synergism and toxicity reduction are achieved.

For minoxidil in a minoxidil-containing formulation to be efficiently absorbed through the scalp, it is important that the formulation blends well with and spreads across the surface of the scalp. In other words, the object of the present invention is to provide a minoxidil-containing topical pharmaceutical composition that blends well with the skin. [Solution] (a) 5-15 w / v% minoxidil, (b) at least one selected from the group consisting of cetylpyridinium and its salts, and benzethonium and its salts, and (c) 8-30 w / v% water, (d) lower alcohol, and (e) 10-30 w / v% polyhydric alcohol. A topical pharmaceutical composition characterized in that the polyhydric alcohol is at least one selected from the group consisting of 1,3-butylene glycol, dipropylene glycol, propylene glycol, glycerin, and polyethylene glycol.

The utility model belongs to the technical field of urethral stents, in particular to a urethral stent with a medicine guide structure, which comprises a urethral stent main body and a shunting groove, the shunting groove is arranged in the urethral stent main body, an annular groove is arranged on one side of the urethral stent main body close to the shunting groove, and the shunting groove is communicated with the annular groove. According to the urethral stent with the medicine guiding structure, after the urethral stent is inserted into the urethra, the urethra is kept unobstructed, when the urethral stent is inserted into the urethra and medicine needs to be applied, the butt joint pipe is rotated, the first thin film is punctured by the puncture needle, the liquid medicine bag is extruded to deform, and liquid medicine in the liquid medicine bag is guided to the urethra wall through the diversion groove; when the liquid medicine in the liquid medicine bag is used up, an injection needle tube and the like are used for puncturing the second film to inject the liquid medicine, the injected liquid medicine is in contact with the urethra wall through the diversion groove, and the urethra support is inserted into the urethra to facilitate local medicine application.

The invention provides hydrogel for treating atopic dermatitis and application thereof, and relates to the technical field of biomedicine, and the hydrogel comprises SA, plasma water, L-G2 and / or FLA. Through in-vitro cytotoxicity tests and antibacterial performance tests, preliminary evaluation is carried out on the hydrogel, it is proved that the hydrogel can inhibit staphylococcus aureus and escherichia coli, meanwhile, the hydrogel shows low cytotoxicity, and the basic requirements of biomedical dressing are met. In animal experiments, by comparing skin lesion conditions before and after AD mouse treatment, it is observed that the hydrogel can significantly improve back skin lesion of a mouse and has a good anti-inflammatory effect. Pathohistological analysis shows that the hydrogel can reduce the thickness of epidermis, inhibit the increase of the TNF-alpha level induced by DNCB and promote inflammation relief. Meanwhile, SA can provide a wet healing environment for skin wounds and is beneficial to promoting wound repair. Therefore, the hydrogel provides a new strategy for AD treatment and management, and is expected to become a novel external medicine for AD treatment.

The invention discloses artificial saliva and a preparation method of artificial saliva hydrogel. The artificial saliva is prepared from the following raw materials in parts by mass: 0.5 to 1 g of KCl, 0.2 to 0.4 g of K2HPO4, 0.2 to 0.8 g of NaCl, 0.2 to 0.4 g of KH2P O4, 10.04 to 20.8 g of CaCl2, 1.5 to 3 g of Nacaboxymethlecellulose, 60 to 120 mg of brown moss alcohol, 495 to 1000 ml of natural coconut juice and 5 to 10 ml of herba sarcandrae extract. By selecting the glabrous sarcandra herb extract, anti-inflammatory and anti-tumor treatment is realized, so that the traditional Chinese medicine composition has a remarkable effect on dry mouth caused by radiotherapy; through the form of a gel bead preparation, the beverage is more portable and unique in taste. The gel beads serve as one of oral local administration preparations, and after the gel beads are exploded, drugs can target small glands which are located below oral mucosa and secrete saliva, and the rapid drug effect is achieved. Direct local administration to the oral mucosa may provide rapid drug action, activate small salivary glands within the buccal mucosa, while avoiding systemic drug exposure and off-target effect.

The invention discloses a periodontal brace for treating periodontitis in Uyghur medicine, and relates to the technical field of auxiliary devices for dental treatment. The tooth socket comprises a customized half-soft membrane tooth socket body, and a medicine storage groove is formed in the inner side of the tooth socket body corresponding to the periphery of gingiva and used for containing Uyghur medicine ointment. The tooth socket is ensured to be fit with the shape of the oral cavity through mold taking customization, the medicine storage groove can prolong the contact time of medicine and periodontium, the medicine storage groove is matched with pure natural Uyghur medicine to avoid the side effect of chemical medicine, and the tooth socket can be repeatedly used. The problems that an existing local treatment medicine is short in treatment effect and obvious in side effect are solved, the treatment effect and safety of chronic periodontitis are improved, and the traditional Chinese medicine composition is suitable for clinical periodontitis local medicine treatment scenes.

This invention provides a hydrogel for treating atopic dermatitis and its applications, relating to the field of biomedical technology. The hydrogel comprises SA, plasma water, L-G2, and / or FLA. Preliminary evaluation of the hydrogel was conducted through in vitro cytotoxicity and antibacterial performance tests, confirming its ability to inhibit Staphylococcus aureus and Escherichia coli. Simultaneously, the hydrogel exhibits low cytotoxicity, meeting the basic requirements for biomedical dressings. In animal experiments, by comparing skin lesions before and after treatment in AD mice, the hydrogel was observed to significantly improve skin lesions on the back of mice, demonstrating good anti-inflammatory effects. Pathological histological analysis showed that the hydrogel can reduce epidermal thickness, inhibit the increase in TNF-α levels induced by DNCB, and promote inflammation relief. Simultaneously, SA can provide a moist healing environment for skin wounds, helping to promote wound repair. Therefore, this hydrogel provides a new strategy for the treatment and management of AD and is expected to become a novel topical drug for AD treatment.

This invention belongs to the field of traditional Chinese medicine technology, and relates to a topical Chinese medicine composition, topical drug, topical patch, acupoint patch, and preparation method and application for treating nausea and vomiting caused by chemotherapy for intracranial tumors. The Chinese medicine composition consists of the following raw materials in parts by weight: 1-2 parts of Ligusticum chuanxiong, 1-2 parts of Gastrodia elata, 2-4 parts of Uncaria rhynchophylla, 1-2 parts of Citrus aurantium, 1-2 parts of Sinapis alba, 1-2 parts of Clematis chinensis, 0.5-1 part of Melia toosendan, 0.5-1 part of Panax ginseng, 1-2 parts of Pinellia ternata, 1-2 parts of Albizia julibrissin bark, 0.5-1 part of Lentinus edodes, and 1-2 parts of Astragalus membranaceus. This Chinese medicine composition has the effects of relieving nausea and vomiting, soothing the liver and strengthening the spleen, detoxifying and eliminating turbidity, calming the liver and extinguishing wind, and calming the mind and soothing the nerves. It not only effectively controls the nausea and vomiting symptoms caused by chemotherapy for intracranial tumors, but also harmonizes the body's Qi and organ functions. The Chinese medicine composition has a simple formula, widely available ingredients, and a simple preparation method; it is for topical application, convenient for clinical use, and has low adverse reactions.

To provide: means for suppressing a decrease in viscosity during long-term storage in a non-aqueous or low-water-content formulation for external application containing sofpironium bromide as an active ingredient; alternatively, a non-aqueous or low-water-content formulation of sofpironium bromide for external application in which a decrease in viscosity during long-term storage is suppressed, the sense of use for patients remains stable, and the formulation exhibits stable pharmaceutical properties; or alternatively, an external formulation of sofpironium bromide that exerts therapeutic effects on diseases involving acetylcholine (for example, primary focal hyperhidrosis).SOLUTION: A pharmaceutical formulation for external application to the human body surface in which a decrease in viscosity during long-term storage is suppressed contains sofpironium bromide, a water-soluble polymer, and ethanol, has a pH of 5.2 or less, and is a uniformly dispersed non-aqueous formulation or a low-water-content formulation having a water content of 5% or less.

The invention discloses an individualized infection control decision-making system based on wound surface microecology and a data processing method, the system collects a local sample of a wound surface, obtains a 16SrDNA or metagenome sequencing result, conventional etiology, inflammation indexes and patient conditions, and records plant defensin BKX-1 and antibacterial drug administration information; the micro-ecological and clinical features are subjected to fusion modeling based on machine learning, a wound infection severity score and a drug resistance risk score are output, an individualized infection control scheme is generated in combination with a preset antibacterial drug use rule, BKX-1 local drug use is preferentially recommended when the risk is low, broad-spectrum antibacterial drugs are reduced, and the risk is reduced. When the risk is high, etiology inspection and medication upgrading are prompted; and data of multiple patients can be counted to form quality indexes such as etiology inspection rate and the like. The method is beneficial to improving the etiology inspection rate, optimizing the use of antibacterial drugs and promoting wound infection control.

Topical pharmaceutical compositions comprising diethylene glycol monoethyl ether (DEGEE) maintained at an acidic pH. The pH of the formulation can be maintained at a pH of less than 6.3, or alternatively less than 6.0. Certain pharmaceutical composition further comprise an emulsifier blend of cetearyl alcohol, dicetyl phosphate, and ceteth-10 phosphate, which is manufactured by Croda under the tradename Crodafos™ CES.

The use of compositions in solid anhydrous form and in the form of a film, which can be reconstituted into semi-solid form at the time of topical application, as well as delivery systems for active ingredients or drugs, the related pharmaceutical compositions, the method for obtaining them and their use are described.

A system and method of applying therapy to a patient includes navigating a dual lumen catheter to a desired segment of bronchus; inflating, via a first tube of the dual lumen catheter, a balloon located on a distal portion of the catheter to isolate the segment bronchial tube; injecting a therapeutic medium into the isolated segment bronchial tube via a second tube of the dual lumen catheter; and retracting the dual lumen catheter to leave the balloon indwelling, where the balloon retains the injected therapeutic medium in the isolated segment bronchial tube.

Disclosed herein are topical pharmaceutical compositions including an effective amount of trolamine salicylate that provide quick and long-lasting pain relief. Disclosed herein are also methods of treating a topical injury or pain with the topical pharmaceutical compositions.

The present invention provides a topical pharmaceutical composition that contains a nonsteroidal anti-inflammatory drug, a lower alcohol, vitamin E derivatives, and water, without the harmful effects caused by high concentrations of alcohol, and without suppressing the precipitation of insoluble substances. [Solution] The topical pharmaceutical composition of the present invention contains (A) a nonsteroidal anti-inflammatory drug, (B) a nonionic surfactant with an HLB value greater than 6.5, (C) 30-45% by weight of a lower alcohol, (D) an antihistamine, (E) 0.1-2% by weight of vitamin E derivatives, (F) 3-6% by weight of monoterpenes, and (G) water.

The purpose of the present invention is to develop a novel method for treating diseases leading to severe corneal and conjunctival epithelial disorder from dysfunction of corneal / conjunctival epithelial stem cells, such as severe ocular surface diseases caused by chronic graft-versus-host disease.　The present invention provides a prophylactic or therapeutic agent for severe ocular surface disease for topical administration, the agent containing apocynin as an active ingredient.

To provide a topical pharmaceutical composition containing indomethacin, diclofenac sodium, felbinac, salicylic acids, or heparins, wherein irritation to the application site is reduced. [Solution] A topical pharmaceutical composition that contains component (A) and component (B) below, wherein component (A) is one or more selected from the group consisting of components (A-1) to (A-5) below, and which reduces irritation to the application site. Ingredient (A-1): Indomethacin Ingredient (A-2): Diclofenac sodium Ingredient (A-3): Felbinac Ingredients (A-4): Salicylic acids Ingredient (A-5): Heparinoid Ingredient (B): One or more selected from the group consisting of loxoprofen, its salts, and their hydrates.

The invention discloses application of a cytisine-N-isoflavone derivative in preparation of a medicine for resisting non-small cell lung cancer, and belongs to the technical field of biological medicine. The derivative is a compound CNI3, and the medicine takes the compound CNI3 or a pharmaceutically acceptable solvate thereof as an active ingredient; the dosage form can be selected from tablets, capsules, granules, dripping pills, suspensions, syrups, enteric preparations, gels, suppositories, ointments, emulsions and injections, and the administration route can be selected from oral administration, injection administration, respiratory tract inhalation administration, local administration, sublingual administration and rectal administration. Experiments in combination with in-vivo cell level and in-vitro animal level prove that the compound CNI3 promotes apoptosis of non-small cell lung cancer, exerts activity of resisting non-small cell lung cancer, has no obvious toxic or side effect on normal tissue cells, is good in safety, and has a good clinical application prospect when being used for preparing the medicine for resisting non-small cell lung cancer.

To provide a topical pharmaceutical composition containing diclofenac in which crystal precipitation is suppressed. [Solution] A topical pharmaceutical composition comprising (A) one or more selected from the group consisting of loxoprofen, its salts and hydrates thereof, (B) one or more selected from the group consisting of diclofenac, its salts and hydrates thereof, and (C) a lower alcohol, wherein the content of the lower alcohol of (C) is 35% by mass or more and 60% by mass or less based on the total mass of the topical pharmaceutical composition, and the pH of the topical pharmaceutical composition is 5.0 to 7.5.

Disclosed herein are topical pharmaceutical compositions including an effective amount of trolamine salicylate that provide quick and long-lasting pain relief. Disclosed herein are also methods of treating a topical injury or pain with the topical pharmaceutical compositions.

Aqueous ocular topical pharmaceutical formulations are provided that deliver an effective amount of (lev)cromakalim or a pharmaceutically acceptable salt thereof to treat an anterior or a posterior ocular disorder that responds to (lev)cromakalim, including glaucoma.

An object of the present invention is to provide a formulation technique for improving the solubility and safety of Prednisolone Valerate Acetate in an external pharmaceutical composition containing Prednisolone Valerate Acetate.SOLUTION: An external pharmaceutical composition comprising Prednisolone Valerate Acetate and propylene glycol monocaprylate.SELECTED DRAWING: None

This invention discloses a recombinant human (or bovine) basic fibroblast growth factor gel with wound-healing and antibacterial functions, and its preparation method. Recombinant human (or bovine) basic fibroblast growth factor gel is a genetically engineered topical drug used clinically to promote healing of burn wounds, chronic wounds, and fresh wounds, with significant efficacy. However, its drawbacks include limited antibacterial properties and inability to be used simultaneously with chemical disinfectants such as iodine and ethanol, which, while promoting wound healing, are not conducive to controlling wound infection. Research has found that protamine sulfate or polylysine, with high safety and good antibacterial properties, can exert good antibacterial and anti-infection functions without negatively affecting the bioactivity and stability of recombinant human (or bovine) basic fibroblast growth factor. This represents an advanced method for preparing recombinant human (or bovine) basic fibroblast growth factor gel with wound-healing and antibacterial functions, enabling this type of drug to better exert its clinical effects and expand its application scope.

A hydrogel is disclosed containing hyaluronic acid esterified at its free hydroxyls with lipoic acid or with lipoic acid and formic acid, or a pharmaceutically acceptable salt thereof, and zinc gluconate; a process for preparing the hydrogel, compositions containing it, and the use of the hydrogel and compositions thereof in the pharmaceutical and cosmetic fields, or as a topical or injectable medical device, are also disclosed.

The invention provides a traditional Chinese medicine preparation for improving the cold treatment effect, namely a cold virus killing agent. The preparation method comprises the following steps: selecting several traditional Chinese medicinal materials with disinfection, sterilization and anti-inflammation functions, namely chrysanthemum indicum, asarum, coptis chinensis, scutellaria baicalensis, pepper, isatis root and liquorice, adding water, boiling twice, mixing the medicine liquids obtained by decocting twice, adding edible white vinegar accounting for 10% of the total medicine amount and an edible preservative accounting for 1% of the total medicine amount, and uniformly stirring. Viruses and bacteria in the nasal cavity can be directly killed; the main path of cold infection is the respiratory tract, the nasal cavity is the leading edge of virus infection, and then cold enters the whole body to cause morbidity; during treatment, the anti-cold drug is orally taken, the drug efficacy spreads all over the whole body, viruses can be quickly killed, but the drug efficacy of nasal mucosa and nasal liquid is difficult to enter, and at the moment, the nasal cavity becomes the base of the anti-cold drug from the leading edge of infection; at the moment, viruses in the nasal cavity can be killed by applying the cold virus killing agent to the nasal cavity, so that the treatment time is saved; the preparation is applied locally, and the efficacy of the preparation cannot reach the whole body, so that a patient must take at least one cold medicine when using the preparation, the cold virus killing agent can be independently used for treating rhinitis, but three medicines, namely magnolia flower, divaricate saposhnikovia root and solidago decurrens, for treating rhinitis must be added.

The invention discloses a polypeptide for topical treatment on skin damages resulting from various causes such as burns, wounds or cuts. The polypeptide topical drugs in different dosage forms have good therapeutic effect on scald models and trauma models of animals with little toxic and side effects, and is an innovative drug with good development prospects, and is effective in topical application in treating skin damages resulting from various causes such as burns, wounds or cuts; safe; low toxic and quality controllable.

Present invention discloses particular peptide sequences of formula (I);(R1)(m)-Xaa1IXaa2T(Q)(p)(R2)(n)  (I) (SEQ ID NO: 1);wherein R1, m, p, n, Xaa1, Xaa2, and R2 have particular meanings, or pharmaceutically or veterinary acceptable salts of these peptides that are effective in the prevention and / or treatment of mammal hair loss.Invention also relates to particular topical pharmaceutical, nutraceutical or veterinary compositions with the peptides of formula (I).

This invention belongs to the field of transdermal drug delivery nanocarrier technology, specifically relating to a nanoliposome using coconut oil as the lipid matrix and a specific Li medicinal herb composition (Alpinia oxyphylla + Artemisia argyi + Patchouli) as a natural penetration enhancer, and its preparation method. This product is a derivative of the core patent "A Natural Transdermal Permeation Enhancer Composition Based on Hainan Li Medicinal Herbs and Its Application" (patent application number: 2026106311990), used to significantly improve the transdermal efficiency and skin retention of the penetration enhancer composition, suitable for topical drugs and functional skin care products, realizing the industrialization extension of the core patent technology.

This invention provides a Skin-Resolved Diffusion (SERS) Detection System for Deep-Resolved Drug Diffusion, comprising a SERS-active microneedle array and a confocal Raman microscope. The SERS-active microneedle array is used for in-situ drug detection at multiple depths in the skin. It consists of polymer microneedles of varying lengths, with noble metal core-shell nanostars uniformly immobilized on their surfaces. Each noble metal core-shell nanostar comprises a noble metal nanostar core modified with an internal standard reporter molecule and an outer noble metal shell. The confocal Raman microscope records the SERS signal generated after the microneedles penetrate the skin. A quantitative model is established by comparing the peak ratio of the target drug characteristic peak to the internal standard characteristic peak in the SERS signal to determine the drug concentration at different depths. This invention enables quantitative analysis of the diffusion behavior of topical drugs at different skin types and depths.